drugset / Trial / NCT02511340
A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP Patients
NaSingle-groupOpen-labelTreatment
Summary
Multi-center, single stage, phase II study to evaluate the efficacy and safety of Flumatinib in accelerated or blastic Phase chronic myelogenous leukemia patients.
Timeline
- Start
- 2013-01
- Primary completion
- 2015-08
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Flumatinib | Small molecule | 600 mg | Oral |